Article
The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial.
Atherosclerosis - 1 Jul 1998
Humphries S E, Luong L A, Talmud P J, Frick M H, Kesäniemi Y A, Pasternack A, Taskinen M R, Syvänne M
Abstract excerpt
The relationship between the 5A/6A stromelysin-1 promoter polymorphism and progression of angiographically determined coronary artery disease (CAD) has been examined in men treated for 32 months with gemfibrozil or placebo in the Lopid Coronary Angiography Trial (LOCAT). The frequency of the 5A a...
Topics
- Aged
- Coronary Angiography
- Coronary Disease
- Disease Progression
- Double-Blind Method
- Gemfibrozil
- Genotype
- Humans
- Hypolipidemic Agents
- Male
- Matrix Metalloproteinase 3
- Middle Aged
- Promoter Regions, Genetic
